BR112017014345A2 - populações de células do rpe e métodos de gerar as mesmas - Google Patents

populações de células do rpe e métodos de gerar as mesmas

Info

Publication number
BR112017014345A2
BR112017014345A2 BR112017014345-3A BR112017014345A BR112017014345A2 BR 112017014345 A2 BR112017014345 A2 BR 112017014345A2 BR 112017014345 A BR112017014345 A BR 112017014345A BR 112017014345 A2 BR112017014345 A2 BR 112017014345A2
Authority
BR
Brazil
Prior art keywords
generating
methods
cell populations
rpe cell
cells
Prior art date
Application number
BR112017014345-3A
Other languages
English (en)
Portuguese (pt)
Inventor
BOHANA-KASHTAN Osnat
Ann Rosenberg Belmaker Lior
Wiser Ofer
Original Assignee
Cell Cure Neurosciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Cure Neurosciences Ltd. filed Critical Cell Cure Neurosciences Ltd.
Publication of BR112017014345A2 publication Critical patent/BR112017014345A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112017014345-3A 2014-12-30 2015-12-30 populações de células do rpe e métodos de gerar as mesmas BR112017014345A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US62/097,753 2014-12-30
US201562116972P 2015-02-17 2015-02-17
US62/116,972 2015-02-17
US201562195309P 2015-07-22 2015-07-22
US62/195,309 2015-07-22
PCT/IL2015/051269 WO2016108239A1 (en) 2014-12-30 2015-12-30 Rpe cell populations and methods of generating same

Publications (1)

Publication Number Publication Date
BR112017014345A2 true BR112017014345A2 (pt) 2018-01-02

Family

ID=55315463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014345-3A BR112017014345A2 (pt) 2014-12-30 2015-12-30 populações de células do rpe e métodos de gerar as mesmas

Country Status (17)

Country Link
US (6) US11891622B2 (https=)
EP (2) EP3674397A1 (https=)
JP (4) JP6882981B2 (https=)
KR (1) KR20170115514A (https=)
CN (1) CN107406830A (https=)
AU (3) AU2015373050B2 (https=)
BR (1) BR112017014345A2 (https=)
CA (1) CA2972575A1 (https=)
DK (1) DK3240892T5 (https=)
EA (1) EA201791416A1 (https=)
ES (1) ES2774456T3 (https=)
HK (1) HK1246348A1 (https=)
IL (4) IL305070B2 (https=)
MX (1) MX2017008737A (https=)
PH (1) PH12017501218A1 (https=)
SG (1) SG11201705379VA (https=)
WO (1) WO2016108239A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
CN114533761A (zh) 2014-12-30 2022-05-27 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
EP3331995A1 (en) * 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
EP3595687A1 (en) * 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
CN109957545A (zh) 2017-12-26 2019-07-02 江苏艾尔康生物医药科技有限公司 一种消化rpe细胞的方法
BR112020013238A2 (pt) * 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
JP2022532411A (ja) * 2019-05-15 2022-07-14 ノヴォ ノルディスク アー／エス ヒト多能性幹細胞から眼野前駆細胞を得るための方法
CN111972399B (zh) * 2020-08-06 2021-11-30 温州医科大学 维持肝细胞活性的保存液
AU2022319764A1 (en) 2021-07-28 2024-01-25 Lineage Cell Therapeutics, Inc. Expansion of retinal pigment epithelium cells
CN115840045B (zh) * 2023-02-23 2023-04-28 中国农业大学 一种猪胚胎期毛囊基板前体细胞的鉴定方法及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
SG49267A1 (en) 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5405742A (en) 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5755785A (en) 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5854015A (en) 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US5941250A (en) 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
GB9715584D0 (en) 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
IL156413A0 (en) 2001-01-31 2004-01-04 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
AU2003201745A1 (en) 2002-02-11 2003-09-04 Pfizer Limited Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2006040763A2 (en) 2004-10-12 2006-04-20 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells and methods of generating and using same
EP2410044B1 (en) 2004-12-29 2022-06-22 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
US20080003676A1 (en) 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
JP5441099B2 (ja) 2007-01-18 2014-03-12 独立行政法人理化学研究所 視細胞への分化誘導方法
ES2527444T5 (es) 2007-04-18 2018-05-17 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
IL292561A (en) 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
US20090226955A1 (en) 2007-12-21 2009-09-10 University Of Miami Immortalized retinal pigmented epithelial cells
JP2009180811A (ja) 2008-01-29 2009-08-13 Canon Inc レンズ鏡筒および撮像装置
KR101025880B1 (ko) 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
AU2010251151B2 (en) 2009-05-20 2015-08-20 Cardio3 Biosciences S.A. Pharmaceutical Composition for the Treatment of Heart Diseases
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
KR20230084328A (ko) 2010-12-30 2023-06-12 셀룰래리티 인코포레이티드 세포의 동결보존 및 캡슐화 방법
US20120258451A1 (en) 2011-04-08 2012-10-11 Advanced Cell Technology, Inc. Laser isolation of viable cells
WO2012149484A2 (en) 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
EP3636286A1 (en) 2011-05-18 2020-04-15 The Regents of The University of California Compositions and methods for treating retinal diseases
TWI719277B (zh) * 2011-11-14 2021-02-21 美商安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
AU2013216382B2 (en) 2012-01-31 2018-08-02 Hadasit Medical Research Services And Development Ltd. Methods of selecting retinal pigmented epithelial cells
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
CN102618497B (zh) 2012-03-15 2013-10-02 中国人民解放军第三军医大学第一附属医院 利用人骨髓间充质干细胞制备视网膜色素上皮细胞的方法
SG11201406336YA (en) 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles
US20150150796A1 (en) 2012-05-30 2015-06-04 Neurotech Usa, Inc. Cryopreserved Implantable Cell Culture Devices and Uses Thereof
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
KR20150032552A (ko) 2012-06-11 2015-03-26 매큐클리어 인코포레이션 치료 제제 및 치료 방법
EP2925856B1 (en) 2012-12-03 2018-03-07 Biolamina AB Methods of producing rpe cells
EP2951290B1 (en) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
CA2933083A1 (en) * 2013-12-11 2015-06-18 Pfizer Limited Method for producing retinal pigment epithelial cells
US20150159134A1 (en) 2013-12-11 2015-06-11 Pfizer Limited Method for producing retinal pigment epithelial cells
AU2014364368A1 (en) 2013-12-20 2016-07-07 Bio-Ess Laboratories, Llc Media for cell culture
WO2015175504A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
WO2015175457A1 (en) 2014-05-12 2015-11-19 Jonathan Allen Rowley Ready-to-print cells and integrated devices
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
CN114533761A (zh) 2014-12-30 2022-05-27 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
WO2017017686A1 (en) 2015-07-29 2017-02-02 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
EP3331995A1 (en) 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
CN105284787A (zh) 2015-10-23 2016-02-03 深圳爱生再生医学科技有限公司 骨髓间充质干细胞的保存试剂及其应用
US12188047B2 (en) 2015-10-26 2025-01-07 Hadasit Medical Research Services And Development Ltd. Preparation of retinal pigment epithelium cells
KR101982801B1 (ko) 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물
EP3595687A1 (en) 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
BR112020013238A2 (pt) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
JP2024522608A (ja) 2021-06-09 2024-06-21 リネージ セル セラピューティクス インコーポレイテッド 網膜の疾患および症状を処置するための方法および組成物

Also Published As

Publication number Publication date
EA201791416A1 (ru) 2017-11-30
IL305070A (en) 2023-10-01
KR20170115514A (ko) 2017-10-17
EP3240892A1 (en) 2017-11-08
JP2018502576A (ja) 2018-02-01
IL253238B (en) 2020-04-30
JP2023052646A (ja) 2023-04-11
US20220169982A1 (en) 2022-06-02
WO2016108239A9 (en) 2017-08-10
MX2017008737A (es) 2018-01-25
US11987810B2 (en) 2024-05-21
US20220154141A1 (en) 2022-05-19
US20220169981A1 (en) 2022-06-02
IL305070B2 (en) 2025-11-01
IL273405B1 (en) 2023-09-01
SG11201705379VA (en) 2017-08-30
US11891622B2 (en) 2024-02-06
JP6882981B2 (ja) 2021-06-02
PH12017501218A1 (en) 2018-01-29
AU2015373050A1 (en) 2017-07-13
HK1246348A1 (zh) 2018-09-07
ES2774456T3 (es) 2020-07-21
EP3674397A1 (en) 2020-07-01
EP3240892B9 (en) 2020-07-22
DK3240892T3 (da) 2020-02-17
JP2025111765A (ja) 2025-07-30
AU2015373050B2 (en) 2022-09-29
DK3240892T5 (da) 2020-10-19
IL321407A (en) 2025-08-01
WO2016108239A1 (en) 2016-07-07
ES2774456T9 (es) 2020-11-05
EP3240892B1 (en) 2019-11-06
AU2015373050A9 (en) 2017-09-07
US20210332325A1 (en) 2021-10-28
CA2972575A1 (en) 2016-07-07
JP2021072832A (ja) 2021-05-13
IL253238A0 (en) 2017-08-31
AU2022291539A1 (en) 2023-02-02
CN107406830A (zh) 2017-11-28
US20240301351A1 (en) 2024-09-12
AU2025237944A1 (en) 2025-10-16
IL273405B2 (en) 2024-01-01
IL305070B1 (en) 2025-07-01
US20180016553A1 (en) 2018-01-18
JP7608192B2 (ja) 2025-01-06
IL273405A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
BR112017014345A2 (pt) populações de células do rpe e métodos de gerar as mesmas
EA201891142A1 (ru) Контроль клеточных окислительно-восстановительных уровней
BR112016025516A2 (pt) composições para controle de mosquito e usos das mesmas
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
MX2016013635A (es) Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
EP4620521A3 (en) Methods and compositions relating to chondrisomes from cultured cells
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
WO2016103269A8 (en) Populations of neural progenitor cells and methods of producing and using same
MX388693B (es) Composiciones de nanoparticulas para terapia sostenida.
AR105602A1 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
EP4374863A3 (en) Methods for generating stem cell-derived beta cells and uses thereof
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112016017584A2 (pt) Composições de nanotribologia e métodos relacionados incluindo nanofolhas moleculares
MX2024001617A (es) Composiciones biofarmaceuticas.
MX376776B (es) Zscan4 para usarse en el tratamiento de enfermedades y condiciones asociadas con una anormalidad de los telómeros.
MY193650A (en) Extracellular matrix compositions
BR112017025325A2 (pt) compósitos elastoméricos termicamente condutores
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
TWD165710S (zh) 電連接器
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
WO2015106043A3 (en) Novel synthetic biology-based adcc technology

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements